Article

Nanopeutics™ s.r.o.

Nanopeutics™ s.r.o. agrees exclusive nanotechnology development partnership with a global leader in professional woundcare

- Partner funding development costs and additional licence fee -

- Successful development will lead to exclusive global royalty bearing licence and supply agreement -

Tuesday, November 14th 2006: Liberec, Czech Republic

Nanopeutics™ s.r.o., (“Nanopeutics”), the medical technnology company dedicated to the commercialisation of Nanospider™ technology for the global woundcare market, today announces that it has signed an exclusive partnership agreement with a world leader in the professional woundcare market.

The agreement is for an exclusive six month period and is focused on the development of a range of nanofibre based professional wound care technologies and products. Under the agreement, all development work and associated costs will be paid for by the Nanopeutics™ partner as well as payment of an associated undisclosed licence fee for the six months exclusivity period.

The successful conclusion to the development work will lead to an exclusive global royalty bearing licence and supply agreement for Nanospider™ based technology and specialist products for the professional woundcare and potential related markets.

The agreement does not cover the consumer wound care market.

Nanopeutics s.r.o. CEO, Camillus Glover, commented:

“This global partnership agreement represents a significant commercial and technological breakthrough into the €10 billion professional woundcare market work.

A specific product and technology development effort is now in place both here at Nanopeutics™ and at the market leading partner, for the development of a range of advanced nanofibre based product applications and technologies and we look forward to further news in this regard in the next six months

We are now in discussions with a number of other woundcare companies for consumer woundcare and other applications.”

Ends

For Further Information Contact: press@nanopeutics.com

Notes to Editors follow:

Nanopeutics™ s.r.o. (“Nanopeutics”) (www.nanopeutics.net) is the specialist Alltracel Pharmaceuticals (AIM: AP.L) (www.alltracel.com) subsidiary formed as part of a joint venture with Elmarco s.r.o. dedicated to the commercialisation of Nanospider™ technology for the global professional and consumer woundcare markets.

Nanopeutics, headquartered in Liberec in the Czech Republic and operating internationally, has been licensed and/or assigned the relevant woundcare and Nanospider™ intellectual property and patents.

Nanospider™ is the novel patented process for spinning polymers into nano-scale fibres for a range of industrial, chemical, micro-electronic and bio-medical applications. The Nanospider™ technology has been recognised internationally as a major breakthrough in the mass production of nanofibre materials.

Nanospider™ and Nanopeutics™ are trademarks controlled by Nanopeutics s.r.o